Sep 2026· Journal of Controlled Release· pp.
115386
· 0 citations· 60 references
Medicine
TL;DR
This study proposes an application-oriented re-engineering strategy that leverages the clinically validated SM-102 platform, enabling rational LNP optimization for diverse mRNA delivery and therapeutic scenarios and recommends SM-102/DSPC and SM-102/DOPE LNPs as preferred formulations for RAW 264.7 macrophages and IGROV1 ovarian cancer cells.
Abstract
Expanding the therapeutic landscape of mRNA medicines to diverse applications necessitates delivery systems tailored to distinct biological requirements. However, beyond vaccine applications, current FDA-approved lipid nanoparticles (LNPs) are often directly used as their original vaccine formulations, substantially limiting their therapeutic potential. Rather than pursuing new ionizable lipids with uncertain safety profiles, we propose an application-oriented re-engineering strategy that leverages the clinically validated SM-102 platform, enabling rational LNP optimization for diverse mRNA delivery and therapeutic scenarios. Through systematic modulation of phospholipid component (e.g., 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)) and lipid molar ratios, we tailor LNPs for transfection across representative cell types in vitro, systemic administration in vivo, and intramuscular delivery in vivo. Consequently, SM-102/DSPC and SM-102/DOPE LNPs emerge as preferred formulations for RAW 264.7 macrophages and IGROV1 ovarian cancer cells, respectively, achieving up to a 25.6-fold enhanced mRNA delivery over original SM-102 LNPs in vitro. For intravenous administration, optimal SM-102/DSPC LNPs enable 2.3-fold enhanced hepatic mRNA delivery compared to original SM-102 LNPs. In contrast, intramuscular injection preferentially benefits from SM-102/DOPE LNPs, achieving 17.7-fold higher muscular expression and 22.0-fold enhanced lymph node delivery than SM-102 LNPs. All optimized formulations show comparable tolerability to the clinically validated SM-102 LNPs. This study supports an application-specific tailoring platform that enables the rational selection of appropriate mRNA delivery systems for diverse therapeutic scenarios.
Recent advancements in ionizable lipid chemistry, microfluidic formulation, and targeted delivery techniques are broadening the therapeutic potential of LNPs, reinforcing their significance as essential carriers in the forthcoming era of precision RNA medicine.
Shayeri Chatterjee Ganguly, Priya Manna, Satadeep Bandyapadhyay et al.· Recent Advances in Drug Deli...· 0 citations
This study successfully develops an optimized formulation with reduced hepatic off-target effects, which holds great promise for the intramuscular delivery of circRNA-based vaccines and therapeutics.
Jie Yang, Yi-Jia Hao, Si-Ying Long et al.· Lab on a Chip· 0 citations
The importance of formulation optimization in improving nucleic acid delivery is highlighted and practical insights for enhancing peptide- and lipid-based therapeutic platforms are provided.
D. Daniele, Z. Hein, O. Saher et al.· International Journal of Pha...· 0 citations
This review presents a unified innovation framework that integrates upstream molecular engineering strategies including cyclization, peptide stapling, D- and β-amino acid substitution, PEGylation, and backbone modification with downstream advanced delivery platforms such as nanocarriers, microneedles, self-assembling h...
Pradip Karale, Saloni Borse, Anjali Gavit et al.· Journal of Pharmaceutical In...· 0 citations
LNPs can be a viable platform for serial and iterative T cell engineering using multiple mRNA payloads, providing an alternative to electroporation for the engineering of therapeutic T cells.
Apoorva Ramamurthy, Giulia Scimonelli, William L. Murphy et al.· Molecular Therapy: Nucleic A...· 0 citations
A structured translational roadmap is proposed that prioritizes biologically predictive design, fit-for-purpose safety assessment, scalable good manufacturing practice production, early regulatory alignment, and clinically meaningful benefit over unnecessary structural complexity.
Yi Li, Rui Luo, Yuxuan Li et al.· Biomedicine & pharmacotherap...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.